Saturday 17 October 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.2% and free cash flow fell 17.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.14
0.05
−4.20%
Follow CLRB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.96 | 2.58 | 0.41 | 1.78 | 9.16 | 16.26 | 4.11 | 8.60 | 4.95 | 7.47 |
Net Debt/EBITDA |
0.58 | 0.45 | 0.25 | 0.69 | 1.49 | 3.77 | 0.76 | 1.15 | 0.83 | 1.26 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% | 0.03% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.06 | 1.07 | 0.76 | 0.79 | 0.94 | 0.92 | 0.83 | 0.74 | 0.73 | 0.88 |
Capex/Depreciation |
(0.03) | (0.36) | (4.49) | (1.52) | (0.94) | (0.44) | (0.18) | (0.19) | (0.22) | (0.20) |
| (200.01%) | 1,470.68% | 732.16% | (159.70%) | (72.63%) | (70.75%) | (151.16%) | (151.08%) | (133.83%) | (130.69%) | |
| (107.74%) | (237.45%) | (254.09%) | (108.15%) | (50.33%) | (42.57%) | (103.23%) | (110.87%) | (106.48%) | (81.67%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,222.58%) | (288.74%) |
Return on Tangible Assets |
(221.49%) | (285.42%) | 309.60% | (336.55%) | (73.26%) | (27.58%) | (155.71%) | (120.26%) | (174.48%) | (77.97%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.11 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(8.87) | (39.07) | (81.67) | (108.29) | (122.82) | (212.05) | (457.74) | (1,189.10) | (2,418.51) | (5,569.67) |
Cash per Share |
5.06 | 19.08 | 23.50 | 84.54 | 193.10 | 866.14 | 414.64 | 1,344.51 | 2,140.72 | 7,666.40 |
Shareholders Equity per Share |
3.27 | 11.71 | (37.25) | 34.69 | 178.72 | 830.22 | 353.88 | 1,339.49 | 2,288.19 | 9,026.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.27 | 11.71 | (37.25) | 34.69 | 178.72 | 830.22 | 353.88 | 1,339.49 | 2,288.19 | 9,026.60 |
Free Cash Flow |
(23.12) | (47.69) | (33.24) | (25.45) | (22.71) | (14.00) | (11.72) | (11.77) | (11.37) | (8.35) |
Working Capital |
9.29 | 14.86 | (14.91) | 9.03 | 32.58 | 54.38 | 8.62 | 12.33 | 8.36 | 10.56 |
Capital Expenditures |
(0.01) | (0.10) | (0.86) | (0.23) | (0.14) | (0.06) | (0.02) | (0.33) | (0.35) | (0.07) |
Net Current Asset Value |
7.60 | 13.07 | (16.78) | 7.09 | 32.41 | 54.08 | 8.19 | 12.16 | 8.36 | 10.41 |
| Other line items | ||||||||||
Quick Ratio |
2.78 | 2.48 | 0.38 | 1.73 | 8.95 | 16.04 | 3.83 | 8.21 | 4.76 | 7.04 |
Depreciation/Fixed assets |
0.39 | 0.39 | 0.18 | 0.35 | 0.44 | 0.40 | 0.31 | 3.24 | 6.32 | 0.25 |
Cash ROIC |
(106.40%) | (126.88%) | 594.23% | (90.82%) | (33.03%) | (12.50%) | (59.56%) | (44.30%) | (54.60%) | (33.36%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(8.86) | (38.98) | (79.55) | (107.33) | (122.06) | (211.10) | (456.79) | (1,155.77) | (2,344.74) | (5,521.47) |
Capex per Share |
0.00 | (0.09) | (2.12) | (0.96) | (0.76) | (0.95) | (0.96) | (33.33) | (73.77) | (48.20) |
Average Payables |
6.00 | 8.38 | 7.33 | 4.67 | 3.65 | 3.05 | 2.10 | 1.71 | 1.64 | 1.05 |
Average Assets |
20.23 | 18.77 | 16.83 | 29.40 | 47.93 | 35.46 | 13.65 | 13.96 | 14.10 | 11.46 |
Average Common Equity |
10.90 | (3.03) | (5.84) | 19.91 | 33.21 | 21.33 | 9.32 | 10.25 | 11.22 | 7.16 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates